USE OF INHALED GASEOUS NITRIC OXIDE AS A MUCOLYTIC AGENT OR EXPECTORANT

Number of patents in Portfolio can not be more than 2000

United States of America Patent

SERIAL NO

14010421

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Methods and devices for treating excess mucus accumulation in mammals by administering gaseous inhaled nitric oxide or nitric oxide releasing compounds as a mucolytic agent or expectorant are provided. Delivery of gaseous nitric oxide can be made nasally or orally and is preferably substantially coincident with inhalation of the mammal or based on a synchronous parameter of the mammal's respiratory cycle. Varying therapeutic profiles may be used for the delivery of gaseous nitric oxide depending on the severity of the excess mucus accumulation. Parameters for the therapeutic profiles may include flow rate of nitric oxide containing gas, duration of administration of nitric oxide containing gas, number of breaths for which nitric oxide containing gas is to be administered, and concentrations of therapeutic NO delivered to the airways.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
PULMONOX TECHNOLOGIES CORPORATION#107 10835 - 120 STREET EDMONTON ALBERTA T5H 3P3

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Hole, Douglas R Edmonton, CA 12 473
Miller, Christopher C North Vancouver, CA 138 24364
Murray, Bruce R Tofield, CA 3 54

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation